Showing results (311-320 of 483) with videos related to
Sort By:
Pageof 49
EJNMMI Research|June 11, 2026
Incidental [68Ga]Ga-DOTATATE uptake in bone metastases of breast carcinoma in a patient with a secondary carcinoid tumorJan Kemle, Sabin G Pop, Alexander Sauter, et al.European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.Oncology Reports|June 4, 2014
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitroClaudia Umbreit, Christoph Aderhold, Anne Faber, et al.Journal of the American Society of Nephrology : JASN|March 3, 2007
Lack of connexin 40 causes displacement of renin-producing cells from afferent arterioles to the extraglomerular mesangiumLisa Kurtz, Frank Schweda, Cor de Wit, et al.Frontiers in Immunology|July 5, 2022
Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage DisplaySteffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, et al.Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.Haematologica|September 25, 2025
Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approachesMaximilian Al-Bazaz, Sven Pischke, Winfried Alsdorf, et al.International Journal of Oncology|March 3, 2007
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neckAlexander Sauter, Charlotte Kloft, Silke Gronau, et al.Journal of Biomedical Materials Research. Part A|February 17, 2018
In vitro cytotoxicity assessment of nanodiamond particles and their osteogenic potentialMohamed Ibrahim, Ying Xue, Melanie Ostermann, et al.Pageof 49